161 related articles for article (PubMed ID: 17587243)
1. Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver.
Takahashi Y; Kawate S; Watanabe M; Fukushima J; Mori S; Fukusato T
Pathol Int; 2007 Jul; 57(7):437-42. PubMed ID: 17587243
[TBL] [Abstract][Full Text] [Related]
2. c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis.
Abou-Elella A; Gramlich T; Fritsch C; Gansler T
Mod Pathol; 1996 Feb; 9(2):95-8. PubMed ID: 8657726
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray.
Wang Y; Wu MC; Sham JS; Zhang W; Wu WQ; Guan XY
Cancer; 2002 Dec; 95(11):2346-52. PubMed ID: 12436441
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of c-myc gene amplification, MTS1/p16 gene alternation, and HBV infection in human hepatocellular carcinoma].
Zhang J; Wang K; Cong S; Qiu F; Wang X; Wang P
Zhonghua Gan Zang Bing Za Zhi; 2001 Oct; 9(5):294-6. PubMed ID: 11676877
[TBL] [Abstract][Full Text] [Related]
5. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
6. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.
Zhang YJ; Jiang W; Chen CJ; Lee CS; Kahn SM; Santella RM; Weinstein IB
Biochem Biophys Res Commun; 1993 Oct; 196(2):1010-6. PubMed ID: 8240318
[TBL] [Abstract][Full Text] [Related]
7. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.
Nishida N; Fukuda Y; Komeda T; Kita R; Sando T; Furukawa M; Amenomori M; Shibagaki I; Nakao K; Ikenaga M
Cancer Res; 1994 Jun; 54(12):3107-10. PubMed ID: 8205525
[TBL] [Abstract][Full Text] [Related]
8. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
Chan KL; Guan XY; Ng IO
Hum Pathol; 2004 Nov; 35(11):1324-31. PubMed ID: 15668888
[TBL] [Abstract][Full Text] [Related]
9. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
[TBL] [Abstract][Full Text] [Related]
11. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-myc gene without gene amplification in human hepatocellular carcinoma.
Wu B; Wang M; You W; Yang S
Chin Med J (Engl); 1996 Dec; 109(12):922-5. PubMed ID: 9275322
[TBL] [Abstract][Full Text] [Related]
13. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
Itatsu K; Zen Y; Ohira S; Ishikawa A; Sato Y; Harada K; Ikeda H; Sasaki M; Nimura Y; Nakanuma Y
Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas.
Tokumoto N; Ikeda S; Ishizaki Y; Kurihara T; Ozaki S; Iseki M; Shimizu Y; Itamoto T; Arihiro K; Okajima M; Asahara T
Int J Oncol; 2005 Oct; 27(4):973-80. PubMed ID: 16142313
[TBL] [Abstract][Full Text] [Related]
16. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
17. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
18. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
19. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
Portolani N; Baiocchi GL; Coniglio A; Piardi T; Grazioli L; Benetti A; Ferrari Bravo A; Giulini SM
Ann Surg Oncol; 2008 Jul; 15(7):1880-90. PubMed ID: 18443881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
